Skip to main content
BEONE MEDICINES LTD. logo

BEONE MEDICINES LTD. — Investor Relations & Filings

Ticker · 688235 ISIN · CNE100005XT6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 728 across all filing types
Latest filing 2022-12-06 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688235

About BEONE MEDICINES LTD.

https://beonemedicines.com/

BEONE MEDICINES LTD. is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutic solutions, primarily in the field of oncology. The company specializes in the discovery of targeted small molecule drugs and biologics designed to address unmet medical needs in cancer treatment. Its research and development pipeline emphasizes precision medicine, utilizing advanced molecular biology and medicinal chemistry platforms to identify novel drug candidates. BEONE MEDICINES LTD. aims to improve patient outcomes by developing high-efficacy, low-toxicity therapies that target specific genetic drivers of disease. The company maintains a strong focus on clinical-stage development and strategic collaborations to advance its portfolio of next-generation medicines.

Recent filings

Filing Released Lang Actions
港股公告：证券变动月报表
Regulatory Filings Classification · 95% confidence The document is a monthly securities movement report for a listed issuer and its Hong Kong Depositary Receipts issuer under Chapter 19B of the Listing Rules. It details changes in registered capital, issued shares, share options, and confirmations related to share issuance and compliance with listing rules. The document is structured as a regulatory monthly report on share capital and share issuance activities, not a financial report, earnings release, or management discussion. It is not an announcement of voting results, board changes, or legal proceedings. The document is a regulatory filing specific to share capital changes and share issuance confirmations, fitting the category of Regulatory Filings (RNS). The document length is 4839 characters, which is substantive but focused on share capital movements and confirmations rather than a full financial report or announcement. Therefore, the best classification is Regulatory Filings (RNS) with high confidence.
2022-12-06 Chinese
港股公告：授出购股权
Share Issue/Capital Change Classification · 95% confidence The document is a formal announcement from BeiGene, Ltd. regarding the grant of share options under the 2016 Option and Incentive Plan. It details the number of options granted, exercise price, vesting schedule, and other terms related to the stock options. The document references the Hong Kong Stock Exchange Listing Rules and provides specific information about the option grant to employees. There is no financial statement, earnings data, or management discussion of financial results. The content is focused on the issuance of stock options, which is a capital-related event. Therefore, this document fits best under the category of Share Issue/Capital Change (SHA), as it announces a change in the company's capital structure through the granting of stock options.
2022-12-02 Chinese
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 95% confidence The document is a disclosure report related to changes in issued share capital and/or share repurchases by the company 百濟神州有限公司, registered in the Cayman Islands and listed on the Hong Kong Stock Exchange. It references specific Hong Kong Stock Exchange Listing Rules (Main Board Rule 13.25A and GEM Rule 17.27A) which require disclosure of share capital changes. The document details share issuance under share award plans, share option exercises, and provides share counts before and after these changes. It also includes confirmations from the company's executive director and CEO regarding the authorization and compliance of these issuances. The document length is about 3,094 characters, which is relatively short but contains detailed data on share issuance and capital changes, not merely an announcement of a report or a certification. This fits the definition of a Share Issue/Capital Change announcement rather than a full financial report or a regulatory filing. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2022-12-01 Chinese
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 95% confidence The document is a disclosure report related to changes in issued share capital and/or share repurchases by the company 百濟神州有限公司, registered in the Cayman Islands and listed on the Hong Kong Stock Exchange. It references specific Hong Kong Stock Exchange Listing Rules (Main Board Rule 13.25A and GEM Rule 17.27A) which require disclosure of share capital changes. The document includes detailed tables of share issuance and repurchase data, dates, share prices, and percentages. It also contains formal confirmations by the company's executive director and CEO regarding the authorization and compliance of the share issuance. The document length is 2878 characters, which is relatively short but contains substantive data on share capital changes, not merely an announcement of a report or a certification. This fits the definition of a Share Issue/Capital Change filing, which covers announcements regarding new share issues, stock splits, or other capital changes. Therefore, the correct classification is SHA (Share Issue/Capital Change).
2022-11-30 Chinese
百济神州有限公司关于召开2022年第三季度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2022 third quarter earnings conference call (业绩说明会) for investors, including time, location, participants, and how investors can ask questions. It references the prior release of the 2022 Q3 report but does not contain any financial data or results itself. The document is short (1581 characters) and serves as a notice for an upcoming earnings call event rather than the call transcript or the financial report. Therefore, it fits best as an Investor Presentation (IP) or possibly a Call Transcript (CT) if it contained the transcript, but since it is only an announcement of the meeting, it is an Investor Presentation (IP) type document describing the earnings call event and investor interaction.
2022-11-22 Chinese
百济神州有限公司自愿披露关于将在美国血液学会2022年会上展示ALPINE试验终期分析结果最新突破摘要的公告
Investor Presentation Classification · 90% confidence The document is a voluntary disclosure announcement by BeiGene Ltd. about the presentation of the final analysis results of the ALPINE clinical trial at the 2022 American Society of Hematology (ASH) annual meeting. It includes details about the trial, drug information, and upcoming investor meetings related to the presentation. The document does not contain actual financial statements or detailed financial analysis but rather announces the event and the content to be presented. The length is under 5,000 characters and it serves as an announcement of a presentation and related investor meetings. Therefore, it fits best as an Investor Presentation (IP) announcement rather than a full report or earnings release.
2022-11-22 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.